Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis

Q: What is the current share price and 52-week range of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd is trading at 195.00 as of 02 September 2026, with a FY2026-2027 high of 289 and low of 108. The stock is currently in the middle of its 52-week range. Market cap stands at 6,329 Cr..

Q: Is Sun Pharma Advanced Research Company Ltd financially healthy?

Key indicators: ROCE of 165 % indicates efficient capital utilization. Dividend yield is 0.00 %.

Fair Value

₹374.14Undervalued by 91.87%vs CMP ₹195.00

P/E (4.0) × ROE (281.0%) × BV (₹41.10) × DY (2.00%)

₹191.75Fairly Valued by 1.67%vs CMP ₹195.00

MoS: -1.7% (Negative)Confidence: 38/100 (Low)Models: 1 Under, 2 Over

Model	Category	Value	Weight	Signal
PE-ROE	Earnings	₹331.91	54%	Under (+70.2%)
Net Asset Value	Assets	₹41.07	26%	Over (-78.9%)
Revenue Multiple	Revenue	₹3.33	20%	Over (-98.3%)
Consensus (3 models)		₹191.75	100%	Fairly Valued

Key Drivers: Wide model spread (₹3–₹332) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -11.3%

*Investments are subject to market risks

Analyst Summary

Sun Pharma Advanced Research Company Ltd operates in the Miscellaneous segment, current market price is ₹195.00, market cap is 6,329 Cr.. At a glance, stock P/E is 3.97, ROE is 281 %, ROCE is 165 %, book value is 41.1, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹191.75, which is broadly in line with the current market price. On operating trend, latest reported sales are about ₹72 Cr versus the prior period change of -5.3%, while latest net profit is about ₹-345 Cr with a prior-period change of 11.1%. The 52-week range shown on this page is 289/108, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisSun Pharma Advanced Research Company Ltd. is a Public Limited Listed company incorporated on 01/03/2006 and has its registered office in the State of Gujarat, India. Company's Corporate Identification…

This summary is generated from the stock page data available for Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

Sun Pharma Advanced Research Company Ltd scores 57/100 (Average)

Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison

Stock Health72/100 · Strong

ROCE 165.0% ExcellentROE 281.0% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent

Smart Money60/100 · Moderate

FII holding up 2.14% (6mo) AccumulatingDII holding down 0.96% MF sellingPromoter holding at 65.7% Stable

Earnings Quality50/100 · Moderate

OPM contracting (-113% → -495%) DecliningWorking capital: -1,778 days (improving) Efficient

Quarterly Momentum25/100 · Weak

Revenue (4Q): -15% YoY DecliningOPM: -673.0% (down 174.0% YoY) Margin pressure

Industry Rank80/100 · Strong

P/E 4.0 vs industry 94.1 Cheaper than peersROCE 165.0% vs industry 31.9% Above peersROE 281.0% vs industry 48.1% Above peers3Y sales CAGR: -19% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 8:10 am

Market Cap	6,329 Cr.
Current Price	195
Intrinsic Value	₹191.75
High / Low	289/108
Stock P/E	3.97
Book Value	41.1
Dividend Yield	0.00 %
ROCE	165 %
ROE	281 %
Face Value	1.00
PEG Ratio	-0.35

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Sun Pharma Advanced Research Company Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Sun Pharma Advanced Research Company Ltd	6,329 Cr.	195	289/108	3.97	41.1	0.00 %	165 %	281 %	1.00
Dredging Corporation of India Ltd	3,085 Cr.	1,102	1,286/538	78.4	444	0.00 %	4.28 %	0.39 %	10.0
Logica Infoway Ltd	302 Cr.	170	244/141	21.3	57.4	0.00 %	13.6 %	14.9 %	10.0
Syngene International Ltd	16,088 Cr.	399	679/375	54.3	120	0.31 %	9.99 %	7.78 %	10.0
Mipco Seamless Rings (Gujarat) Ltd	8.90 Cr.	24.8	27.3/20.5	35.6	3.35	0.00 %	37.0 %	%	10.0
Industry Average	6,451.00 Cr	260.97		94.10	104.56	0.05%	31.88%	48.06%	9.00

All Competitor Stocks of Sun Pharma Advanced Research Company Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	131	48	24	21	14	17	17	13	15	27	10	8	8
Expenses	115	137	126	113	116	124	112	117	89	81	62	74	65
Operating Profit	16	-90	-102	-91	-103	-108	-95	-104	-74	-54	-52	-66	-57
OPM %	12%	-188%	-427%	-432%	-740%	-649%	-566%	-808%	-499%	-198%	-543%	-838%	-673%
Other Income	0	11	10	8	6	4	2	0	0	0	9	0	-12
Interest	3	0	0	0	0	1	1	1	3	5	6	8	9
Depreciation	3	3	3	3	3	3	3	3	3	3	3	3	3
Profit before tax	10	-82	-95	-86	-100	-107	-97	-108	-80	-61	-52	-76	-81
Tax %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	10	-82	-95	-86	-100	-107	-97	-108	-80	-61	-52	-76	-81
EPS in Rs	0.37	-2.53	-2.94	-2.66	-3.07	-3.29	-2.98	-3.32	-2.46	-1.88	-1.60	-2.34	-2.48

Last Updated: March 3, 2026, 2:30 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 12:16 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	167	156	161	181	78	183	77	253	137	239	76	72	53
Expenses	134	191	224	304	321	334	387	388	324	453	479	399	282
Operating Profit	34	-35	-63	-123	-243	-151	-310	-135	-187	-214	-404	-327	-229
OPM %	20%	-23%	-39%	-68%	-310%	-83%	-404%	-53%	-136%	-90%	-534%	-456%	-431%
Other Income	10	3	3	14	54	14	10	5	7	11	29	2	-3
Interest	6	0	2	2	0	0	3	11	13	8	2	9	27
Depreciation	4	7	8	8	8	8	9	11	10	12	12	11	10
Profit before tax	34	-40	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345	-270
Tax %	12%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Profit	30	-40	-70	-119	-197	-145	-312	-151	-203	-223	-388	-345	-270
EPS in Rs	1.23	-1.60	-2.83	-4.82	-7.85	-5.55	-11.92	-5.77	-7.48	-6.86	-11.96	-10.64	-8.30
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-233.33%	-75.00%	-70.00%	-65.55%	26.40%	-115.17%	51.60%	-34.44%	-9.85%	-73.99%	11.08%
Change in YoY Net Profit Growth (%)	0.00%	158.33%	5.00%	4.45%	91.94%	-141.57%	166.77%	-86.04%	24.58%	-64.14%	85.07%

Sun Pharma Advanced Research Company Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	-7%
5 Years:	-1%
3 Years:	-19%
TTM:	-6%

Compounded Profit Growth
10 Years:	%
5 Years:	-2%
3 Years:	-30%
TTM:	23%

Stock Price CAGR
10 Years:	-9%
5 Years:	-4%
3 Years:	-14%
1 Year:	-36%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Last Updated: September 5, 2025, 1:36 pm

Balance Sheet

Last Updated: July 22, 2026, 5:30 am

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	24	24	25	25	26	26	26	27	32	32	32	32
Reserves	76	8	133	160	270	-45	-194	4	480	92	-253	1,301
Borrowings	4	56	3	2	2	67	236	79	16	56	265	559
Other Liabilities	39	75	111	122	101	224	162	170	302	305	284	275
Total Liabilities	143	163	273	309	398	273	230	280	830	486	329	2,168
Fixed Assets	67	70	69	52	58	104	91	92	106	103	95	85
CWIP	0	1	1	3	24	32	5	26	27	44	54	72
Investments	0	0	10	108	211	8	6	12	291	2	0	0
Other Assets	76	92	192	146	106	128	127	150	406	338	179	2,011
Total Assets	143	163	273	309	398	273	230	280	830	486	329	2,168

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity +	-41	-44	-128	-183	-172	-211	-152	-208	-69	-429	-362	-239
Cash from Investing Activity +	53	-13	-7	-105	-102	155	2	-29	-548	391	158	-24
Cash from Financing Activity +	-1	51	194	224	274	55	159	229	617	43	201	262
Net Cash Flow	11	-7	60	-63	0	0	9	-8	-1	4	-4	-1
Free Cash Flow	-49	-56	-136	-200	-184	-264	-153	-233	-84	-455	-372	-262
CFO/OP	110%	48%	88%	71%	111%	65%	111%	114%	35%	105%	114%	-17%

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	34.00	-39.00	-119.00	-126.00	-245.00	-153.00	-377.00	-371.00	-266.00	-230.00	-460.00	-592.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	61	47	21	78	82	20	76	25	74	50	75	82
Inventory Days		0	0	0	0	0	0	0	0
Days Payable
Cash Conversion Cycle	61	47	21	78	82	20	76	25	74	50	75	82
Working Capital Days	127	20	-161	-60	-232	-98	-842	-268	-301	-193	-746	-1,778
ROCE %	21%	-32%	-71%	-94%	-143%	-62%	-183%	-242%	-218%	-67%	-109%	-298%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	65.68%	65.68%	65.68%	65.68%	65.68%	65.68%	65.68%	65.67%	65.67%	65.67%	65.67%	65.68%
FIIs	3.67%	3.30%	3.24%	2.64%	2.15%	2.23%	1.45%	1.47%	1.76%	2.04%	2.04%	3.90%
DIIs	0.65%	0.67%	0.67%	0.17%	0.21%	0.64%	1.13%	0.97%	1.05%	0.78%	0.88%	0.09%
Public	29.99%	30.36%	30.41%	31.51%	31.96%	31.47%	31.76%	31.88%	31.52%	31.51%	31.41%	30.34%
No. of Shareholders	1,01,433	1,03,990	1,02,743	1,25,184	1,28,205	1,31,034	1,42,864	1,40,724	1,36,997	1,44,810	1,40,625	1,41,957

Shareholding Pattern Chart

No. of Shareholders

Sun Pharma Advanced Research Company Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund	1,767,774	0.38	25.29	2,413,308	2026-06-09 16:02:10	-26.75%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23
FaceValue	1.00	1.00	1.00
Basic EPS (Rs.)	-10.55	-11.93	-7.82
Diluted EPS (Rs.)	-10.55	-11.93	-7.82
Cash EPS (Rs.)	-10.17	-11.55	-6.50
Book Value[Excl.RevalReserv]/Share (Rs.)	-6.68	3.88	15.80
Book Value[Incl.RevalReserv]/Share (Rs.)	-6.68	3.88	15.80
Revenue From Operations / Share (Rs.)	2.21	2.33	7.36
PBDIT / Share (Rs.)	-9.90	-11.48	-6.26
PBIT / Share (Rs.)	-10.28	-11.87	-6.62
PBT / Share (Rs.)	-10.56	-11.92	-6.86
Net Profit / Share (Rs.)	-10.55	-11.93	-6.86
NP After MI And SOA / Share (Rs.)	-10.55	-11.93	-6.86
PBDIT Margin (%)	-447.77	-493.24	-85.09
PBIT Margin (%)	-465.04	-509.80	-90.01
PBT Margin (%)	-477.63	-512.05	-93.21
Net Profit Margin (%)	-477.25	-512.55	-93.21
NP After MI And SOA Margin (%)	-477.25	-512.55	-93.21
Return on Networth / Equity (%)	0.00	-307.91	-43.40
Return on Capital Employeed (%)	862.23	-154.06	-33.00
Return On Assets (%)	-102.07	-75.18	-26.81
Long Term Debt / Equity (X)	-0.46	0.00	0.00
Total Debt / Equity (X)	-1.19	0.37	0.00
Asset Turnover Ratio (%)	0.16	0.11	0.00
Current Ratio (X)	0.07	1.02	2.54
Quick Ratio (X)	0.07	1.02	2.54
Interest Coverage Ratio (X)	-35.55	-219.89	-26.61
Interest Coverage Ratio (Post Tax) (X)	-36.89	-227.50	-28.15
Enterprise Value (Cr.)	5059.27	11897.66	5712.17
EV / Net Operating Revenue (X)	70.50	157.49	23.92
EV / EBITDA (X)	-15.74	-31.93	-28.11
MarketCap / Net Operating Revenue (X)	66.93	158.92	24.39
Price / BV (X)	-22.14	95.47	11.36
Price / Net Operating Revenue (X)	66.93	158.93	24.39
EarningsYield	-0.07	-0.03	-0.03

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Sun Pharma Advanced Research Company Ltd and is it undervalued?

As of 02 September 2026, Sun Pharma Advanced Research Company Ltd's intrinsic value is ₹191.75, which is 1.67% lower than the current market price of ₹195.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (281 %), book value (₹41.1), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd is trading at ₹195.00 as of 02 September 2026, with a FY2026-2027 high of ₹289 and low of ₹108. The stock is currently in the middle of its 52-week range. Market cap stands at ₹6,329 Cr..

How does Sun Pharma Advanced Research Company Ltd's P/E ratio compare to its industry?

Sun Pharma Advanced Research Company Ltd has a P/E ratio of 3.97, which is below the industry average of 94.10. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Sun Pharma Advanced Research Company Ltd financially healthy?

Key indicators for Sun Pharma Advanced Research Company Ltd: ROCE of 165 % indicates efficient capital utilization; ROE of 281 % shows strong shareholder returns. Dividend yield is 0.00 %.

Is Sun Pharma Advanced Research Company Ltd profitable and how is the profit trend?

Sun Pharma Advanced Research Company Ltd reported a net profit of ₹-345 Cr in Mar 2025 on revenue of ₹72 Cr. Compared to ₹-203 Cr in Mar 2022, the net profit shows a mixed trend.

Does Sun Pharma Advanced Research Company Ltd pay dividends?

Sun Pharma Advanced Research Company Ltd has a dividend yield of 0.00 % at the current price of ₹195.00. The company is currently not paying meaningful dividends.